Ultima Genomics

We are thrilled that Linda Ramirez-Eaves has joined Ultima as Chief Legal Officer. Linda has nearly 30 years of experience practicing law, with over a decade in the life sciences and biotechnology industry. Prior to joining Ultima, Linda was the General Counsel of Olink, a leading provider of next-generation proteomics solutions. There, she led Olink through a successful initial public offering on the Nasdaq and subsequent rounds of fundraising, culminating in its 2024 acquisition by Thermo Fisher Scientific. Read more: https://lnkd.in/gABXfiSv #NGS #healthcare #biotech #lifesciences #UG100

In collaboration with the New York Genome Center, our teams have recently published a study in Nature Cell Biology involving systematic #Perturbseq of signaling regulators (2.6M cells, 6 cell lines, 1500 perturbations). This work introduces an improved computational framework (Mixscale) to address cellular variation in perturbation efficiency and demonstrates how our Perturb-seq derived gene lists can be used to precisely infer changes in signalling pathway activation for in vivo and in situ samples. This lays a computational framework towards the data-driven inference of an ‘atlas’ of perturbation signatures. Congratulations to all authors including: Rahul Satija, Gila Lithwick Yanai, Nika Iremadze Read the publication here: https://rdcu.be/ecr9I #NGS #UG100 #SingleCell #FunctionalGenomics Nature Portfolio

A warm thank you to, Alex Dickinson, for hosting our CEO, Gilad Almogy, on his new Geonomics Podcast. Next Generation Sequencing (#NGS) continues to be a game changer for many disciplines and we are excited for our technology to be at the forefront of areas like the #BIOAI moment in helping accelerate drug discoveries and #MRD for post-cancer screening assay development. #NGS #ppmSeq #WGS #SingleCell #Proteomics #AI #UG100 #healthcare #pharma ?

Lots of technology advancements were shared at this year’s AGBT - Advances in Genome Biology and Technology conference and we were thrilled to be a part of the relentless pursuit of this unwavering community to push the limits of what is possible in advancing human health. ? View our Silver II workshop on demand: https://lnkd.in/gU56_E4n ?? ?? Commercial launch of UG 100 SolarisTM ?? ?? 50% more reads per wafer and 20% reduction in cost ?? New, simplified workflows – Solaris Free and Solaris Flex ?? Up to 50% increase in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome ?? Generate more than 30,000 whole genomes per year ?? Improved sensitivity with 80% of SNVs above SNVQ60 with ppmSeq for MRD, now with increased yield providing 30x WGS coverage from 2 nanograms of cfDNA ?? Early access availability of UG 100 Solaris Boost, a new high-throughput operating mode providing up to 100 billion reads per day for select short read applications ?? Expanded access to affordable sequencing ?? ? Access to #UG100 just got easier with the addition of leading genomic services providers.?These providers include Broad Clinical Labs, Eurofins, Novogene, Psomagen and Ontario Institute for Cancer Research. Existing partners include Inocras Inc., Macrogen Inc., and the University of Minnesota Genomics Center. ? If you are thinking about your next #singlecell, #spatial, #proteomics, and/or #WGS project, consider reaching out to one of our global service providers. Sequencing costs shouldn’t prevent you from moving your research forward. At less than half the cost of other sequencing technologies on the market, with Ultima, you can #keepthechange. Start saving today. #NGS #AI #humanhealth #Pharma #ppmSeq #MRD

AI meets BIO. We are excited to support Compugen's capabilities in predictive computational discovery of new drug targets and development of new cancer immunotherapies. This work was showcased at this week's #AGBTGM. Our high-throughput, cost-effective #UG100 sequencer is enabling researchers to unlock new applications and insights through transformative economics supporting larger scale. Read more: https://lnkd.in/gsRzUs_W #AI #AIBIO #ImmunoOncology #SingleCell #NGS #healthcare

$80 a genome. $0.24 per million reads. If this got your attention - our Service Providers are offering a special 'AGBT-only' promotion on all Ultima services. At half the cost of other sequencing technologies on the market, stop wasting money and #keepthechange. ?? Who is eligible: AGBT attendees ?? Limited time only: project purchase order submitted ty April 30 ?? Maximum: 20 wafers at 10B reads per wafer ?? One use per customer lab ?? Mention promo codes when ordering (see below) University of Minnesota Genomics Center Ontario Institute for Cancer Research Novogene Inocras Inc. Psomagen #AGBTGM #UG100 #NGS #omics #SingleCell #Proteomics #WGS

Pushing the boundaries of cutting-edge technologies through collaboration and vision. We are proud to be partnering with key thought leaders in the field. What will you do with cost-effective sequencing? Ultima Silver Workshop Gilad Almogy, PhD | CEO & Founder | Ultima Genomics Taylor Jensen, PhD?| Vice President | Head of Oncology Science?| Labcorp Chris Whelan, PhD | Director | Johnson & Johnson Innovative Medicine Jonah Cool, PhD | Science Program Officer | Chan Zuckerberg Initiative Niall J Lennon, PhD | CSO and Chair| Broad Clinical Labs | Ultima AI + BIO Coffee Talk Eric Jaschke, CFA | VP, Business Development | Ultima Genomics Johnny Yu, PhD | CSO and Co-Founder | Vevo Therapeutics Jonah Cool, PhD | Science Program Office | Chan Zuckerberg Initiative TJ C., PhD | Healthcare Life Sciences | NVIDIA Healthcare #AGBTGM #NGS #UG100 #AI #AIBIO #SingleCell #Proteomics #Healthcare

AI meets BIO. An exciting day for Vevo Therapeutics as they have fully open-sourced the 100M #singlecell dataset, Tahoe-100M, generated using the #UG100 and the GigaLab at Parse Biosciences. Next step is for NVIDIA Healthcare to train disease-relevant foundation models of human cells on this and other Vevo-generated data. #AIBIO #NGS #healthcare #OpenSource #Tahoe100M?

Access to affordable sequencing with the #UG100 just got easier! We are expanding around the globe with the addition of multiple new partnerships with leading genomic services providers.?Thinking about your next #singlecell, #spatial, #proteomics, and #WGS project? At less than half the price of other competitors on the market, with Ultima, you can #keepthechange. New partners include: Broad Clinical Labs Eurofins Novogene Psomagen Ontario Institute for Cancer Research Existing partners: Macrogen Inc. Inocras Inc. University of Minnesota Genomics Center Learn more: https://lnkd.in/gNFfRJBT #NGS #SequencingServices #Genomics #Omics #AI #AIBIO

Ultima is thrilled to announce the commercial launch of UG 100 Solaris - new product advancements that make the #UG100 sequencer even more powerful and cost-effective. ?? Get more for less - 50% more reads per wafer and 20% reduction in cost ?? Run more ‘omics' applications with new, simplified workflows – Solaris Free and Solaris Flex ?? Up to 50% increase in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome ?? Ability to generate more than 30,000 whole genomes per year ?? Improved sensitivity with 80% of SNVs above SNVQ60 with ppmSeq for MRD, now with increased yield providing 30x WGS coverage from 2 nanograms of cfDNA ?? Early access availability of UG 100 Solaris Boost, a new high-throughput operating mode providing up to 100 billion reads per day for select short read applications Sequencing costs shouldn’t prevent you from moving your research forward. At less than half the cost of other sequencing technologies, with Ultima, you can ‘keep the change’. Start saving today. Read more here: https://lnkd.in/guwmSM5T Access UG 100 technology today: https://lnkd.in/dvH4Z5WF #keepthechange #NGS #omics #SingleCell #Proteomics #WGS #ppmSeq #cfDNA #MRD